MacroGenics Provides Corporate Update and 2022 Financial Results
15. März 2023 16:01 ET
|
MacroGenics, Inc.
Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readoutEncouraging lorigerlimab...
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
08. März 2023 17:36 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
07. März 2023 18:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
02. März 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
13. Februar 2023 17:20 ET
|
MacroGenics, Inc.
Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90%...
MacroGenics to Participate in Upcoming Investor Conferences
06. Februar 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04. Januar 2023 17:50 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics...
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
04. Januar 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
17. November 2022 18:10 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
03. November 2022 16:01 ET
|
MacroGenics, Inc.
Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-endAnticipated update...